{"text": "nvs s curious car t journey continues after squandering its haem onc lead to gild amp bmy it puts lupus ahead of dlbcl and multiple myeloma story via gt"}
{"text": "nvs ceo says its full steam ahead for car t in immunology which is a top priority initial programme in sle will be expanded into other indications when safety data generated admits it will be a race with bmy but sounds like novartis is getting ready to go big here"}
{"text": "bmy the answer is obviously no 700mm fy22 luspatercept sales for the 30 of r r lr mds patients who are rs gern"}
{"text": "auph plan is in motion step 1 withhold ceo greenleaf withhold chairman milne withhold comp committee hagan vote no 3 amp 4 bmy jnj nvs gsk pfe mrk abbv lupkynis"}
{"text": "placed emphasis on driving r amp d productivity by prioritizing high value medicines across our five core therapeutic areas of cardiovascular immunology neuroscience solid tumors lets go nvs lt gt jump ahead of gild amp bmy amp pfe in the race for best neo tcr t platform"}
{"text": "my roundup of the nvs q1 call and details of the 10 pipeline cull in hindsight was news of a big push for car t into immunology the most interesting statement via bmy gild"}
